Abstract
The macrocycles representing a unique chemical structure bridging conventional small molecules and large biomolecules, have attracted more and more attention in drug discovery over the past decade, and tremendous progress has been made toward the macrocyclization synthesis and structure diversification recently. Because of their favored size, flexibility and complexity, macrocycles can engage previously undruggable targets through numerous and spatially distributed binding interactions, and offer many privileged features including high potency, prominent selectivity, as well as favorable pharmacokinetics properties, and unique intellectual property(IP) space, and even safety profiles, etc. Currently around 70 macrocyclic molecules have been approved for clinical therapy, over 76 macrocycles are being evaluated in clinical trials from phase I to phase III. It is believed that the macrocycles will play more and more important role in the future, and provide very distinctive and promising opportunities for drug discovery along with the development of synthetic methodology, phenotypical screening, and computational studies.
Keywords: Macrocycle, Macrocyclic peptide, Macrolide, Macrocyclization, Infection disease, Oncology, Drug discovery.
Current Pharmaceutical Design
Title:Macrocyclic Compounds: Emerging Opportunities for Current Drug Discovery
Volume: 22 Issue: 26
Author(s): Lisha You, Rui An, Kun Liang, Bo Cui and Xinhong Wang
Affiliation:
Keywords: Macrocycle, Macrocyclic peptide, Macrolide, Macrocyclization, Infection disease, Oncology, Drug discovery.
Abstract: The macrocycles representing a unique chemical structure bridging conventional small molecules and large biomolecules, have attracted more and more attention in drug discovery over the past decade, and tremendous progress has been made toward the macrocyclization synthesis and structure diversification recently. Because of their favored size, flexibility and complexity, macrocycles can engage previously undruggable targets through numerous and spatially distributed binding interactions, and offer many privileged features including high potency, prominent selectivity, as well as favorable pharmacokinetics properties, and unique intellectual property(IP) space, and even safety profiles, etc. Currently around 70 macrocyclic molecules have been approved for clinical therapy, over 76 macrocycles are being evaluated in clinical trials from phase I to phase III. It is believed that the macrocycles will play more and more important role in the future, and provide very distinctive and promising opportunities for drug discovery along with the development of synthetic methodology, phenotypical screening, and computational studies.
Export Options
About this article
Cite this article as:
You Lisha, An Rui, Liang Kun, Cui Bo and Wang Xinhong, Macrocyclic Compounds: Emerging Opportunities for Current Drug Discovery, Current Pharmaceutical Design 2016; 22 (26) . https://dx.doi.org/10.2174/1381612822666160204114838
DOI https://dx.doi.org/10.2174/1381612822666160204114838 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteinase-Activated Receptor-2: Physiological and Pathophysiological Roles
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Novel Inflammatory Indices in Aortic Disease
Current Medicinal Chemistry Retinal Vascular Features for Cardio Vascular Disease Prediction: A Review
Recent Patents on Computer Science β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Aliskiren: A Novel Renin Inhibitor for Hypertension
Current Drug Therapy Pulmonary Hypertension and Right Ventricular Dysfunction in Chronic Lung Diseases: New Pathobiologic Concepts
Current Respiratory Medicine Reviews Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Current Psychopharmacology Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy
Current Neurovascular Research Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Statins for Diabetic Cardiovascular Complications
Current Vascular Pharmacology Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets Studying the Human Gut Microbiota in the Trans-Omics Era - Focus on Metagenomics and Metabonomics
Current Pharmaceutical Design Personalized and Participatory Medicine as a Future Tool to Combat Cardiovascular Disease in Developing Countries
Current Pharmacogenomics and Personalized Medicine Circulating Cellular Players in Vascular Calcification
Current Pharmaceutical Design Cardioprotective Potential of Iron Chelators and Prochelators
Current Medicinal Chemistry